A cost-benefit analysis of anti-influenza vaccination in a company in Italy (Snamprogetti);Analisi costi-benefici di una strategia vaccinale antinfluenzale condotta presso una società del gruppo ENI (Snamprogetti)

PharmacoEconomics - Italian Research Articles

Volumn 3, Issue 2, 2001, Pages 71-80

  Colombo, G L ^a   Nicosia, V ^b   Lesma, A ^b   Madera, A ^b   Caruggi, M ^c   Serra, G ^d  

^a SAVE Studi Analisi Valutazioni Economiche   (Italy)

^b ENI S P A   (Italy)

^c Ospedale Civile di Legnano   (Italy)

^d GSK   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 6044225173     PISSN: 15909158     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03320581     Document Type: Article

References (23)

1. Cate TR. Clinical manifestations and consequences of influenza. Am J Med 1987; 82: 15-9
2. Neuzil KM, Reed GW. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA 1999; 281(10): 901-7
3. Nicholson KG. Socioeconomics of influenza and influenza vaccination in Europe. PharmacoEconomics 1996; 9 (suppl. 3): 75-8
4. Ministero della Sanità. Circolare n. 11/1999. Profilassi antinfluenzale.
5. Sullivan KM. Health impact of influenza in the United States. PharmacoEconomics 1996; 9 (suppl. 3): 26-33
6. Knottnerus JA. Influenza in the Netherlands. PharmacoEconomics 1996; 9 (suppl. 3): 46-9
7. Gasparini R, Pozzi T, Bonanni P, Fragapane E. Valutazione dei costi di un'epidemia influenzale nella popolazione lavorativa di Siena. Giornale di Farmacoeconomia 2000; 1: 3-9
8. Postma MJ, Bos JM, Van Gennep M. Economic evaluation of influenza vaccination. PharmacoEconomics 1999; 16 (suppl. 1): 33-40
9. Kumpulainen V, Makela M. Influenza vaccination among healthy employees: a cost-benefit analysis. Scand J Infect Dis 1997; 29: 181-5
10. Levy E. French economic evaluations of influenza and influenza vaccination. PharmacoEconomics 1996; 9 (suppl. 3): 62-6
11. Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995; 333 (14): 889-93
12. Wilde JA, McMillan JA, Serwint J, et al. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA 1999; 281(10): 908-13
13. Breiman RF, Butler JC, McInnes PM. Vaccine to prevent respiratory infection: opportunities on the near and far horizon. Current Opinion in Infectious Diseases 1999; 12: 145-52
14. Drummond MF, Stoddard GL, Torrance GW. Methods for the economic Evaluation of Health Care Programmes. Oxford: Oxford Medical Publications, 1997
15. Sloan FA. Valuing Health Care. Cambridge: Cambridge University Press, 1995
16. Freund DA, Dittus RS. Principles of pharmacoeconomic analysis of drug therapy. PharmacoEconomics 1992; 1 (1): 20-32
17. Lucioni C. Costi e benefici della vaccinazione. Vaccinazione 2000 1995; 7, 37 (suppl.): 31-7
18. Sobal J, Loveland FC. Infectious disease in a total institution: a study of the influenza epidemic of 1978 on a college campus. Public Health Rep 1982; 97 (1): 66-72
19. Lucioni C, Sessa A, Costa B. I costi dell'influenza in Italia. Farmeconomia e percorsi terapeutici 2001; 1 (1): 11-8
20. Koplan JP. The benefits and costs of immunization revisited. Drug Information Journal 1988; 22: 379-83
21. van der Oever R, de Graeve D, Hepp B, et al. Pharmaeconomics of immunization. A review. PharmacoEconomics 1993; 3 (4): 286-308
22. Conway SP, Leese B. Routine childhood immunisation. It is worth it? PharmacoEconomics 1993; 3 (3): 183-91
23. ISTAT. Rivalutazione monetaria. Indici prezzi al consumo 2001. Consultabile all'indirizzo http://www.istat.it/Anotizie/Acom/precon/indiceistat/variazioni.htm